Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29107450 | 1.00 | FFAR1 (0.55) | FFAR1GAAHTTMAPK1TP53 | |
| SCHEMBL21121221 | 0.91 | FFAR1 (0.54) | FFAR1GAAHTTMAPK1EPHX2 | |
| SCHEMBL21121220 | 0.91 | FFAR1 (0.54) | FFAR1GAAHTTMAPK1EPHX2 | |
| SCHEMBL21121327 | 0.88 | FFAR1 (0.70) | FFAR1 | |
| SCHEMBL21121329 | 0.88 | FFAR1 (0.70) | FFAR1 | |
| SCHEMBL22800011 | 0.88 | FFAR1 (0.70) | FFAR1 | |
| SCHEMBL21121487 | 0.84 | FFAR1 (0.57) | FFAR1MAPK1SMN1; SMN2 | |
| SCHEMBL21121488 | 0.84 | FFAR1 (0.57) | FFAR1MAPK1SMN1; SMN2 | |
| SCHEMBL22823950 | 0.82 | GAA (0.58) | GAAHTTMAPK1TP53SMN1; SMN2 | |
| SCHEMBL21121146 | 0.82 | FFAR1 (0.55) | FFAR1MAPK1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964938-B2 | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | CELON PHARMA S.A. (PL) | 2024-04-23 | — | — | US | disclosed |
| EP-3737470-B9 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | Celon Pharma Sa (PL) | 2024-03-13 | — | — | EP | disclosed |
| CN-111757770-B | 3-Phenyl-4-hexynoic acid derivatives as GPR40 agonists | 赛隆制药股份公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-3737470-B1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | Celon Pharma Sa (PL) | 2022-12-14 | — | — | EP | disclosed |
| WO-2019134984-A1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | CELON PHARMA S.A. (PL) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964938-B2 | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | GPR119, FFAR1, GPR65 | FFAR1 2/4885GAA 3620/4885HTT 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.